Down 16% on Nov 6 while the S&P 500 rose 0.3%.
Follow INO's trial news. Pro members can get an alert when Inovio Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 110.2% more shares than a year ago |
| Latest filing | 8-K, Nov 10 |
ReportToday after the close: a loss of $0.50 a share. Past reports ›
Mon Nov 9Form 8K Inovio Pharmaceuticals Inc For: 9 November By Investing.com
Expected to report Thu Mar 11, after the close
The company says its cash lasts into late fourth quarter 2027 (8-K, Nov 9).
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
INO is #252 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 252 |
Net income over four quarters: INO -$67.4M, NRXP -$23.5M, SVRA -$153M.
Expected to report Thu Mar 11, after the close (in 121 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.50 a share, from $0.87.
“The increase in net loss was primarily driven by a $26.9 million non-cash loss on fair value adjustment related to our warrant liabilities for the three months ended September 30, 2026, compared to a $22.5 million non-cash loss for the same period in 2025.”
INO's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Operational net cash burn | about $21M |
“The increase was due to the anticipated launch of VOCERYQ.”
From its results filing (SEC filing · Nov 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 12, 2026 | +5.2% | +16.9% | +68.8% |
| May 13, 2026 | -3.7% | +1.5% | -8.2% |
| Mar 12, 2026 | +2.4% | -1.2% | -1.8% |
Sales grew in two of the last seven years, to $65K in 2025. It lost money in each of the eight years.
RSI 56.1, MACD above signal, above both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: INO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
“As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing.”
INO scores -7 today, which Breakaway calls Poor. It is #252 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 16% on Nov 6 while the S&P 500 rose 0.3%. Shares: 2.1 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
INO scores -7 today, which Breakaway calls Poor (below zero). That is #252 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind INO's -7.
Expected to report Thu Mar 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. INO closed higher after 2 of its last 3 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.